Japan Cardiovascular Drugs Market Analysis Report 2022 to 2030

Japan Cardiovascular Drugs Market Analysis

$ 3999

Japan Cardiovascular Drug Market is at around $8.56 Bn in 2022 and is projected to reach $12.04 Bn in 2030, exhibiting a CAGR of 4.30% during the forecast period. Due to changes in modern lifestyle, the prevalence of cardiovascular disease has been rising. The market is dominated by key players like Otsuka Holdings Co Ltd., Takeda Pharmaceutical Co Ltd., Daiichi Sankyo Co Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, and Novartis AG.

ID: IN10JPPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Aneri Parekh

Buy Now

Japan Cardiovascular Drug Market Executive Summary

Japan Cardiovascular Drug Market is at around $8.56 Bn in 2022 and is projected to reach $12.04 Bn in 2030, exhibiting a CAGR of 4.30% during the forecast period.

Cardiovascular diseases are ailments of the heart and blood vessels combined. These include coronary heart disease, rheumatic heart disease, peripheral artery disease, congenital heart disease, deep vein thrombosis, and pulmonary embolism. Angiotensin-II antagonists (like losartan), antiarrhythmics (like amiodarone), and ACE inhibitors (like ramipril) are the three primary classes of medications used to treat heart-related issues.

The aging population in Japan is driving up demand for heart disease treatments, which is driving up the market for cardiovascular medications. Despite the dominance of generics, branded medications are becoming more popular as awareness and cost decrease.

Pharmaceutical income has increased dramatically during the past 20 years, and in 2022 it reached $138.33 Bn worldwide. The market for cardiovascular medications in Japan is affected by several variables, such as changes in lifestyle, demographic trends, medical technology breakthroughs, legislative frameworks, and the incidence of cardiovascular illnesses.

Esperion Therapeutics and Otsuka Pharmaceutical collaborated to produce and market bempedoic acid tablets, NEXLETOL and NEXLIZET. The partnership aims to offer patients in Japan suffering from hypercholesterolemia with affordable oral LDL-cholesterol-lowering solutions.

Japan cardiovascular drug market

Market Dynamics

Market Growth Drivers:

High Prevalence of Cardiovascular Disorders: One major factor driving the need for cardiovascular medications is the rising incidence of cardiovascular disorders, such as hypertension, coronary artery disease, and heart failure, among the Japanese population.

Aging Population: The need for cardiovascular drugs to manage and treat age-related cardiovascular disorders is growing as the population ages.

Technological Advancements: New medications and treatment options for cardiovascular disorders are developed as a result of advances in medical research and technology. The market is growing as a result of the release of new, more potent drugs.

Market Restraints:

Challenges to the Japanese Healthcare System: The market for cardiovascular medications may be impacted by issues with the distribution of resources, reimbursement practices, and access to specialized cardiovascular care.

Adverse Effects and Safety Concerns: Patients may be less compliant with their cardiovascular treatment regimens and, in certain situations, the drugs may be withdrawn from the market, which could have an impact on sales and market expansion.

Clinical Trial Failures: Pharmaceutical companies may suffer financial losses and delays in releasing new treatments onto the market as a result of clinical trials for novel cardiovascular medications failing.

Healthcare Policies and Regulatory Landscape

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) is the regulatory body that collaborates with the Ministry of Health, Labour, and Welfare. The NDA dossier and the necessary payments must be sent to the PMDA. After reviewing the NDA dossier, the PMDA may ask for more details. The PMDA will authorize the medication for sale in Japan if they approve the NDA dossier. Japan has a very thorough and strict drug approval process. A New Drug Application (NDA) must be submitted and is subject to thorough review. This procedure adds to the complexity of drug control in Japan by guaranteeing that only medications that fulfill the highest quality criteria are allowed to be sold.

Competitive Landscape

Key Players:

Otsuka Holdings Co Ltd.
Takeda Pharmaceutical Co Ltd.
Daiichi Sankyo Co Ltd.
Bristol-Myers Squibb Company
Pfizer Inc.
Bayer AG
Janssen Pharmaceuticals, Inc.
AstraZeneca
Sanofi
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Others

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.